



The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島成立之有限公司)

(Stock code 股份代號: 3933)

NOTIFICATION LETTER 通知信函

26 September 2022

Dear Non-registered Holder^(Note),

The United Laboratories International Holdings Limited (the “Company”) **— Notice of Publication of 2022 Interim Report (“Current Corporate Communication”)**

The English and Chinese versions of the Company’s Current Corporate Communication are available on the Company’s website at www.tul.com.cn and the HKExnews’ website at www.hkexnews.hk. You may access the Current Corporate Communication by clicking “Investor Relations” on the homepage of our website, then selecting “Financial Reports” and viewing them through Adobe® Reader® or browsing through the HKExnews’ website.

If you want to receive a printed version of the Current Corporate Communication, please complete the Request Form on the reverse side and return it to the Company c/o Computershare Hong Kong Investor Services Limited (the “Hong Kong Branch Share Registrar”) by using the mailing label at the bottom of the Request Form (no need to affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the Hong Kong Branch Share Registrar is 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. The Request Form may also be downloaded from the Company’s website at www.tul.com.cn or the HKExnews’ website at www.hkexnews.hk.

Should you have any queries relating to any of the above matters, please call the Company’s telephone hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays or send an email to tul3933.ecom@computershare.com.hk.

By Order of the Board of
The United Laboratories International Holdings Limited
Leung Wing Hon
Company Secretary

Note: This letter is addressed to Non-registered holders (“Non-registered holder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Request Form on the reverse side.

各位非登記持有人^(附註)：

聯邦制藥國際控股有限公司（「本公司」） **— 2022 年中期報告（「本次公司通訊文件」）之發佈通知**

本公司的本次公司通訊文件中、英文版本已上載於本公司網站 (www.tul.com.cn) 及香港交易所披露易網站 (www.hkexnews.hk)，歡迎瀏覽。請在本公司網站主頁按「投資者關係」一項，再選擇「財務報告」並使用 Adobe® Reader® 開啟查閱或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本次公司通訊文件之印刷本，請填妥在本函背面的申請表格，並使用隨附之郵寄標籤寄回本公司經香港中央證券登記有限公司（「香港股份過戶登記分處」）（如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票）。香港股份過戶登記分處地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。申請表格亦可於本公司網站 (www.tul.com.cn) 或香港交易所披露易網站 (www.hkexnews.hk) 內下載。

如對本函內容有任何疑問，請致電本公司電話熱線 (852) 2862 8688，辦公時間為星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正或電郵至 tul3933.ecom@computershare.com.hk。

承董事會命
聯邦制藥國際控股有限公司
公司秘書
梁永康

2022 年 9 月 26 日

附註：此函件乃向本公司之非登記持有人（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向本公司發出通知，希望收到公司通訊文件）發出。如果閣下已經出售或轉讓所持有之本公司股份，則無需理會本函件及所附申請表格。